Key references: Contraindications, benefits and harms of systemic MHT
Baber RJ, Panay N, Fenton A, Group IMSW. IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric 2016;19(2):109–50. https://www.ncbi.nlm.nih.gov/pubmed/26872610
Boardman HM, Hartley L, Eisinga A, Main C, Roque i Figuls M, Bonfill Cosp X, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev 2015;(3):CD002229. https://www.ncbi.nlm.nih.gov/pubmed/25754617
Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol 2012;13(11):1141–51. https://www.ncbi.nlm.nih.gov/pubmed/23084519
Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008;107(1):103–11. https://www.ncbi.nlm.nih.gov/pubmed/17333341
Gartlehner G, Patel SV, Feltner C, Weber RP, Long R, Mullican K, et al. Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: evidence report and systematic review for the US Preventive Services Task Force. JAMA 2017;318(22):2234–49. https://www.ncbi.nlm.nih.gov/pubmed/29234813
Maki PM, Henderson VW. Hormone therapy, dementia, and cognition: the Women's Health Initiative 10 years on. Climacteric 2012;15(3):256–62. https://www.ncbi.nlm.nih.gov/pubmed/22612612
Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA 2013;310(13):1353–68. https://www.ncbi.nlm.nih.gov/pubmed/24084921
Marsden JBritish Menopause Society. British Menopause Society consensus statement: The risks and benefits of HRT before and after a breast cancer diagnosis. Post Reprod Health 2019;25(1):33–7. https://www.ncbi.nlm.nih.gov/pubmed/30773990
Oliver-Williams C, Glisic M, Shahzad S, Brown E, Pellegrino Baena C, Chadni M, et al. The route of administration, timing, duration and dose of postmenopausal hormone therapy and cardiovascular outcomes in women: a systematic review. Hum Reprod Update 2019;25(2):257–71. https://www.ncbi.nlm.nih.gov/pubmed/30508190
Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004;291(24):2947–58. https://www.ncbi.nlm.nih.gov/pubmed/15213206
Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JV, et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015;100(11):3975–4011. https://www.ncbi.nlm.nih.gov/pubmed/26444994
Villa P, Amar ID, Shachor M, Cipolla C, Ingravalle F, Scambia G. Cardiovascular risk/benefit profile of MHT. Medicina (Kaunas) 2019;55(9). https://www.ncbi.nlm.nih.gov/pubmed/31500138
Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ 2019;364:k4810. https://www.ncbi.nlm.nih.gov/pubmed/30626577
